Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News

Pharma News

Takeda group begins manufacturing COVID-19 plasma treatment ahead of approval
Takeda group begins manufacturing COVID-19 plasma treatment ahead of approval
NEW YORK (Reuters) - The Takeda Pharmaceutical Co-led group that is developing a blood plasma treatment for COVID-19 has started manufacturing while the late-stage trial to determine whether i...
GAO details ongoing problems with FDA's lab safety oversight
GAO details ongoing problems with FDA's lab safety oversight
The US Government Accounting Office (GAO) found that many elements of an effort to improve laboratory safety at the Food and Drug Administration (FDA) have not been met, over three yea...
New Zealand signs deal with Pfizer, BioNTech for COVID-19 vaccine
New Zealand signs deal with Pfizer, BioNTech for COVID-19 vaccine
SYDNEY (Reuters) - The New Zealand government signed a deal on Monday to buy 1.
ViiV posts positive long-term data for two-drug HIV regimen Dovato
ViiV posts positive long-term data for two-drug HIV regimen Dovato
GlaxoSmithKline subsidiary ViiV Healthcare has reported new data for its two-drug HIV regimen Dovato, with hopes that the long-term data could encourage clinicians to switch from other triple regimen ...
Amgen's big cardiovascular bet with Cytokinetics hits PhIII primary but dramatically disappoints investors
Amgen's big cardiovascular bet with Cytokinetics hits PhIII primary but dramatically disappoints investors
A closely watched heart drug from Amgen and Cytokinetics has both hit the primary endpoint on a major trial and dramatically disappointed investors.
Eli Lilly in deal to supply COVID-19 drugs to low-income countries
Eli Lilly in deal to supply COVID-19 drugs to low-income countries
(Reuters) - Eli Lilly and Co LLY.
Pfizer's breast cancer drug Ibrance fails late-stage study
Pfizer's breast cancer drug Ibrance fails late-stage study
(Reuters) - Pfizer Inc said on Friday its cancer drug Ibrance did not meet the main goal in a late-stage trial in patients with a type of breast cancer, the latest setback in the company’s a...
Women's expected longevity linked to age at birth of last child
Women's expected longevity linked to age at birth of last child
CLEVELAND, Ohio -- No one knows for sure how long they will live.
80-year-old antibiotic redesigned for new medical uses. Synthetic strategy to enhance natural chemistry
80-year-old antibiotic redesigned for new medical uses. Synthetic strategy to enhance natural chemistry
Physicians and scientists have long searched the natural world for chemicals that can improve human health.
China in talks with WHO over assessing its COVID-19 vaccines for global use
China in talks with WHO over assessing its COVID-19 vaccines for global use
SINGAPORE (Reuters) - China is in talks to have its locally-produced COVID-19 vaccines assessed by the World Health Organization, as a step toward making them available for international use, ...
Takeda strikes $1B biobucks deal with Arrowhead for genetic liver disease asset
Takeda strikes $1B biobucks deal with Arrowhead for genetic liver disease asset
As Arrowhead continues its turnaround, this election cycle is looking like a new era compared to the last as it strikes a major billion-dollar deal with Takeda.
Neurocrine Biosciences and Xenon Pharmaceuticals Provide Regulatory Update on Ongoing Collaboration to Develop First-In-Class Treatment for Epilepsy
Neurocrine Biosciences and Xenon Pharmaceuticals Provide Regulatory Update on Ongoing Collaboration to Develop First-In-Class Treatment for Epilepsy
SAN DIEGO and BURNABY, British Columbia, Oct.
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand